Cochrane Abstracts
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease: Cochrane systematic review
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease: Cochrane systematic review is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Tolerability of Selective Cyclooxygenase 2 Inhibitors Used for the Treatment of Rheumatological Manifestations of Inflammatory Bowel Disease: Cochrane Systematic Review." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/434725/all/Negative_pressure_wound_therapy_for_partial‐thickness_burns_New_search_for_studies_and_content_updated__no_change_to_conclusions_. Accessed 21 March 2023.
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease: Cochrane systematic review. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/434725/all/Negative_pressure_wound_therapy_for_partial‐thickness_burns_New_search_for_studies_and_content_updated__no_change_to_conclusions_. Accessed March 21, 2023.
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease: Cochrane systematic review. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/434725/all/Negative_pressure_wound_therapy_for_partial‐thickness_burns_New_search_for_studies_and_content_updated__no_change_to_conclusions_
Tolerability of Selective Cyclooxygenase 2 Inhibitors Used for the Treatment of Rheumatological Manifestations of Inflammatory Bowel Disease: Cochrane Systematic Review [Internet]. In: Cochrane Abstracts. [cited 2023 March 21]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/434725/all/Negative_pressure_wound_therapy_for_partial‐thickness_burns_New_search_for_studies_and_content_updated__no_change_to_conclusions_.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease: Cochrane systematic review
ID - 434725
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/434725/all/Negative_pressure_wound_therapy_for_partial‐thickness_burns_New_search_for_studies_and_content_updated__no_change_to_conclusions_
DB - Evidence Central
DP - Unbound Medicine
ER -
